<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03098823</url>
  </required_header>
  <id_info>
    <org_study_id>AMP-002</org_study_id>
    <nct_id>NCT03098823</nct_id>
  </id_info>
  <brief_title>A Crossover Study to Compare RAYOS to IR Prednisone to Improve Fatigue and Morning Symptoms for SLE</brief_title>
  <acronym>RIFLE</acronym>
  <official_title>A Randomized, Double-Blind, Active Comparator-Controlled, Crossover Study to Assess the Capacity of RAYOS® Compared to Immediate-Release Prednisone to Improve Fatigue and Control Morning Symptoms in Subjects With Systemic Lupus Erythematosus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ampel BioSolutions, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ampel BioSolutions, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the effect of RAYOS® versus immediate-release (IR) prednisone on fatigue as
      measured by Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 12, 2017</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fatigue</measure>
    <time_frame>3 months</time_frame>
    <description>Fatigue as measured in FACIT-F by patient</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">62</enrollment>
  <condition>Lupus Erythematosus, Systemic</condition>
  <condition>Lupus Erythematosus</condition>
  <condition>Fatigue</condition>
  <arm_group>
    <arm_group_label>RAYOS®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>IR prednisone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RAYOS</intervention_name>
    <description>FDA approved RAYOS for indication of fatigue in Lupus.</description>
    <arm_group_label>RAYOS®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>FDA approved corticosteroid frequently used for SLE.</description>
    <arm_group_label>IR prednisone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Provide written informed consent agreeing to all study procedures, before any
             study-specific procedures are done.

          2. Males or non-pregnant females, aged 18 years or older

          3. Diagnosis of SLE by either the American College of Rheumatology (ACR) or Systemic
             Lupus International Collaborating Clinics Classification (SLICC) criteria

          4. Fatigue measured by FACIT-F ≤30.

          5. On a stable regimen of IR prednisone (5 to 15 mg/day) for a period of at least 30 days
             prior to Screening, expected to remain stable for the next 6 months.

          6. On a stable SLE treatment regimen for a period of at least 30 days prior to Screening,
             and expected to remain stable for the next 6 months. Any of the following medications
             are permitted if stable for at least 30 days prior to Screening and expected to remain
             stable for the next 6 months:

               -  Hydroxychloroquine or equivalent anti-malarial

               -  Other immunosuppressive or immunomodulatory agents including methotrexate,
                  azathioprine, leflunomide, mycophenolate (including mycophenolate sodium or
                  mycophenylate mofetil at no more than 2 grams/day), belimumab, cyclophosphamide,
                  calcineurin inhibitors (e.g. tacrolimus, cyclosporine)

          7. Entry of daily ePRO data on 11 of 14 days during the baseline period, and completion
             of at least 6 out of the 8 weekly ePRO questionnaires during the baseline period

          8. Willing and able to perform and comply with all study procedures, including taking
             pills daily as prescribed, completing the ePROs on the smart phone, wearing the smart
             watch day and night, bringing the smartphone on all activities away from home (e.g.,
             walks, errands, visiting, shopping, traveling), keeping the smartphone and smartwatch
             charged daily, carefully using the smartphone and smartwatch as clinical tools and
             keeping them secure from others, and attending monthly clinic visits as scheduled

          9. Females of childbearing potential must be currently using a highly effective method of
             contraception that may include, but is not limited to, abstinence, sex only with
             persons of the same sex, monogamous relationship with vasectomized partner,
             hysterectomy, bilateral tubal ligation, licensed hormonal methods, intrauterine
             device, or use of a spermicide combined with a barrier method (e.g., condom,
             diaphragm) for 30 days before and 90 days after receiving the study drug

        Exclusion Criteria:

          1. Previously taken any of the following medications:

               -  RAYOS®

               -  Rituximab within 6 months prior to Screening

               -  Any investigational therapy within 3 months or 5 half-lives of the agent prior to
                  Screening

          2. History of noncompliance with taking pills as prescribed.

          3. Rapidly progressive neurologic disease

          4. Rapidly progressive renal disease (defined by proteinuria &gt;6 g/24 hours or equivalent
             using spot urine protein to creatinine ratio, or serum creatinine &gt;2.5 mg/dL)

          5. Diagnosis of fibromyalgia

          6. Any of the following clinical laboratory abnormalities:

               -  Hemoglobin &lt;8.0 mg/dL

               -  Platelet count &lt;50,000/mm3

               -  White blood count (WBC) ≤ 2000/mm3; may be 1999-1000/mm3 if stable and related to
                  SLE

               -  Absolute neutrophil count (ANC) ≤1000/mm3; may be 500-999/mm3 if stable and
                  related to SLE

               -  Aspartate transaminase (AST) or alanine transaminase (ALT) ≥3× upper limit of
                  normal (ULN) unless related to SLE

               -  Calculated creatinine clearance ≤25 mL/min per 1.73 m2 (by Cockcroft-Gault
                  equation)

          7. Grade 3 or greater laboratory abnormality based on the National Cancer Institute
             Common Terminology Criteria for Adverse Events (CTCAE; Appendix 3) except for the
             following that are allowed:

               -  Activated partial thromboplastin time (PTT) &gt; &gt;2.5× ULN due to lupus
                  anticoagulant and not related to liver disease or anti-coagulant therapy

               -  Hypoalbuminemia &lt;2 g/dL due to chronic lupus nephritis, and not related to liver
                  disease

               -  Gamma glutamyl transferase (GGT) &lt;20× ULN due to lupus hepatitis, and not related
                  to alcoholic liver disease, uncontrolled diabetes, or viral hepatitis. If
                  present, any abnormalities in the ALT and/or AST must be ≤5× ULN

          8. Pregnant or nursing, or females not using effective contraception

          9. Current drug or alcohol abuse or dependence, or a history of drug or alcohol abuse or
             dependence within 1 year prior to Screening

         10. Clinical evidence of significant unstable or uncontrolled acute or chronic diseases
             not caused by SLE (e.g., diabetes, cardiovascular, pulmonary, hematologic,
             gastrointestinal, neurological, or infectious) which, in the opinion of the
             Investigator, could confound the results of the study or put the subject at undue risk
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Rebecca Bender</last_name>
    <phone>434-477-2675</phone>
    <email>rebeccabender@ampel.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Wallace</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Regents of the University of California, Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maureen McMahon</last_name>
      <phone>310-825-9447</phone>
      <email>mmcmahon@mednet.ucla.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California-Irvine</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sheetal Desai</last_name>
      <phone>714-456-5135</phone>
      <email>sheetald@uci.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Genovese</last_name>
      <phone>650-498-5630</phone>
      <email>genovese@stanford.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Regents of the University of California, San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kenneth Kalunian</last_name>
      <phone>858-657-7049</phone>
      <email>kkalunian@ucsd.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California-San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Dall'Era</last_name>
      <phone>415-502-1886</phone>
      <email>maria.dallera@ucsf.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yale School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fotios Koumpouras</last_name>
      <phone>203-785-2454</phone>
      <email>fotios.koumpouras@yale.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Florida College of Medicine</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Bubb</last_name>
      <phone>352-294-8203</phone>
      <email>bubbmr@medicine.ufl.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Miller School of Medicine at the University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Carpintero</last_name>
      <phone>305-243-0151</phone>
      <email>mcarpintero@med.miami.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Mahieu</last_name>
      <phone>312-503-1919</phone>
      <email>mary-mahieu@northwestern.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meenakshi Jolly</last_name>
      <phone>312-563-2800</phone>
      <email>meenakshi_jolly@rush.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Maryland School of Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Violeta Rus</last_name>
      <phone>410-706-3205</phone>
      <email>vrus@umaryland.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Stone</last_name>
      <phone>617-724-7732</phone>
      <email>jhstone@mgh.harvard.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UMASS Memorial Medical Center-Memorial Campus</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathon Kay</last_name>
      <phone>508-334-6273</phone>
      <email>jonathon.kay@umassmemorial.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Hospital for Special Surgery</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kyriakos Kirou</last_name>
      <phone>212-606-1728</phone>
      <email>kirouk@hss.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anca Askanase</last_name>
      <phone>212-305-0856</phone>
      <email>ada20@cumc.columbia.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of North Carolina at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Saira Sheikh</last_name>
      <phone>919-966-0576</phone>
      <email>szsheikh@email.unc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The MetroHealth System</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stanley Ballou</last_name>
      <phone>216-778-5846</phone>
      <email>sballou@metrohealth.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oklahoma Medical Research Foundation</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katherine Thanou</last_name>
      <phone>405-271-7805</phone>
      <email>katherine-thanou@omrf.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nancy Olsen</last_name>
      <phone>717-531-4921</phone>
      <email>nolsen@pennstatehealth.psu.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Temple University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Caricchio</last_name>
      <email>roc@temple.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 21, 2017</study_first_submitted>
  <study_first_submitted_qc>March 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 4, 2017</study_first_posted>
  <last_update_submitted>January 11, 2018</last_update_submitted>
  <last_update_submitted_qc>January 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatigue</mesh_term>
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

